Not published trials, both recruiting and not recruiting, targeting MAPK pathway

NCT Phase Status Tumors Line of treatment Target Experimental treatment Standard treatment Primary endpoints Sponsor
NCT00397384 1 Completed eCCA Non specified KRAS wild type Erlotinib + Cetuximab N.A. MTD No-profit
NCT04190628 1 Recruiting CCA NTA BRAF V600 mutation ABM-1310 N.A. MTD/RP2D Profit
NCT04566133 1 Not yet recruiting CCA NTA KRAS mutation Trametinib + HCQ N.A. PFS Profit

HCQ: hydroxychloroquine